PROGRAMME

1 June | 1st Day

	ROOM A	ROOM B
14.00	Opening session	
14.30 15.00 15.30	Update in cancer-associated thrombosis (CAT) Extracellular vesicles in CAT pathogenesis NOACs or LMWH for cancer-associated VTE Assessment of bleeding risk Tailoring anticoagulation beyond six months	Emerging technologies and thrombosis Artificial intelligence in managing thrombosis Nanoparticles in thrombosis research Modulating Lp(a) to reduce thrombus burden? Circulating miRNAs in the pathophysiology of atherosclerosis and thrombosis
16.00	Coffee and poster exhibition	
16.30	Dilemmae in antithrombotic treatment in CAD Is there a place for P2Y12 pre-treatment in STEMI? Antithrombotic treatment beyond the first year of ACS Hypofibrinolysis in CAD: how to tailor management?	Thromboeie, immunity and inflammation DIC a thrombotic microangiopathy in sepsis and COVID-19 Von Willebrand Factor and inflammation: a new key role beyond haemostasis From basic science to therapeutics of platelet GP VI
17.30	Laboratory measurements of platelet function and NOACs Monitoring platelet function: is it worth it?	What the oliniciane should know about COVID-19 Soluble biomarkers of thrombosis in COVID-19
18.00	Functional assays in the diagnosis of Heparin-Induced Thrombocytopenia Laboratory testing in patients treated with NOACs	The interplay between inflammation and thrombosis in COVID-19 Vaccines: where we are ?



28th International Congress on Thrombosis Lisbon Marriott Hotel, Portugal | 1-3 June 2023 -----

PROGRAMME

2 June | 2nd Day

	ROOM A	ROOM B			
08.30					
09.00	Moderated posters	Case based session			
09.30					
10.00	Managing antithrombotio therapy in ohallenging scenarics Anticoagulation in mesenteric thrombosis	New concepts, new options, new targets for treatment Novel antiplatelet agents in ischemic CV disease			
10.30	Indications for endovascular management in VT Patients with cancer at risk of thrombocytopenia	Factors XI and XII as targets for new anticoagulants. Factor XI in arterial vascular disease			
11.00	Coffee and poster exhibition				
11.30	The different faces of thrombosis Thrombosis in Hemoglobinopathies	Thrombotio diseases in the paediatrio age Thrombosis in neonates, children, adolescents and young adults			
12.00	Cancer-associated pulmonary embolism Antineoplastic treatment modalities: Effects on coagulation	NOAC and DVT in children- are we there? Thrombophilia causing in utero thrombosis: what 's new?			
12.30	Antiphospholipid syndrome	Anticoagulant treatment of paediatric cancer patients			
13.00					
13.30	Satellite symposium /sponsored session	Satellite symposium / sponsored session			
14.00					

Morning sessions

Afternoon sessions

	ROOM A	ROOM B
14.00	Main Leoture «JOSÉ ANTONIO IRIARTE»	Main leoture Personalized medicine in thrombosis
14-30	Inherited thrombophiliae	The fine balance between thrombosis and bleeding
	Thrombophilia testing in daily practice: who and when?	Pregnancy and need for anticoagulation
15.00	Genetics as a powerful tool in prediction of VT	Current place for monitoring NOACs
	Paediatric Thrombophilia	Reversal agents, new developments
15.30	Update in clinical guidelines for thrombophilia testing	Anticoagulation and bleeding in ECMO
16.00	Coffee and poster exhibition	
16.30	Practical eccesion: how to do it How long should we treat children with DVT?	Tipe and tricke for the young investigator The perspective of a basic scientist
17.00	Aspirin in the primary prevention setting	The perspective of a clinician
17.30	Satellite symposium /sponsored session	Satellite symposium /sponsored session
18.00		
18.30	EMLTD General Assembly	



28th International Congress on Thrombosis Lisbon Marriott Hotel, Portugal | 1-3 June 2023



PROGRAMME

3 June | 3rd Day



On I hrombosis
Lisbon Marriott Hotel, Portugal | 1-3 June 2023

Afternoon sessions

	ROOM A	ROOM B
14.00	Main leoture «MICHEL SAMAMA" Thromboeie in women: gender differences	Main Leoture Nutrition, Mediterranean diet and atherothromboeie
14-30 15.00	Core Currioulum Session Bleeding «the dark side of the moon» Thrombotic microngiopathies Monotherapy after acute coronary syndromes. Less is more?	Managing antithrombotic therapy in challenging econarice Mechanical valve prosthesis and major bleeding Transcatheter valve replacement in the very old population Thrombosis and bleeding in liver disease
15.30	Thrombosis and bleeding in liver disease Factor XI inhibition. A big promise Bleeding Risk Assessment in end-stage kidney disease	Atrial fibrillation and high-risk or spontaneous intracranial bleeding Invasive procedures in patients with high bleeding risk
16.00	Closing session and awards	